Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21

Trends in Endocrinology and Metabolism

Volumn 26, Issue 1, 2015, Pages 22-29

  Owen, Bryn M ^a   Mangelsdorf, David J ^a,b   Kliewer, Steven A ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Arginine vasopressin; Brown adipose tissue; Corticotropin releasing factor; Hypothalamus; Sympathetic nervous system; Klotho

Indexed keywords

BETA KLOTHO PROTEIN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 15; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 21; KLOTHO PROTEIN; UNCLASSIFIED DRUG; FGF19 PROTEIN, HUMAN;

ADIPOSE TISSUE; DRUG EFFECT; HORMONE ACTION; HUMAN; LIVER; METABOLIC DISORDER; NERVOUS SYSTEM; NONHUMAN; PHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; ANIMAL; ANTIBODY SPECIFICITY; DRUG EFFECTS; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY;

ADIPOSE TISSUE; ANIMALS; DIABETES MELLITUS, TYPE 2; FIBROBLAST GROWTH FACTORS; HUMANS; LIVER; METABOLIC DISEASES; OBESITY; ORGAN SPECIFICITY;

EID: 84920483737     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2014.10.002     Document Type: Review

References (93)

1. Beenken A., Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat. Rev. Drug Discov. 2009, 8:235-253.
2. Goetz R., et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol. Cell. Biol. 2007, 27:3417-3428.
3. Hu M.C., et al. Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu. Rev. Physiol. 2013, 75:503-533.
4. Potthoff M.J., et al. Endocrine fibroblast growth factors 15/19 and 21: from feast to famine. Genes Dev. 2012, 26:312-324.
5. Inagaki T., et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005, 2:217-225.
6. Choi M., et al. Identification of a hormonal basis for gallbladder filling. Nat. Med. 2006, 12:1253-1255.
7. Fon Tacer K., et al. Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol. Endocrinol. 2010, 24:2050-2064.
8. Markan K.R., et al. Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes 2014, Published online July 9, 2014. http://dx.doi.org/10.2337/db14-0595.
9. Badman M.K., et al. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007, 5:426-437.
10. Inagaki T., et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 2007, 5:415-425.
11. Lundasen T., et al. PPARalpha is a key regulator of hepatic FGF21. Biochem. Biophys. Res. Commun. 2007, 360:437-440.
12. Lee J.H., et al. The transcription factor cyclic AMP-responsive element-binding protein H regulates triglyceride metabolism. Nat. Med. 2011, 17:812-815.
13. Potthoff M.J., et al. FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:10853-10858.
14. Coskun T., et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008, 149:6018-6027.
15. Inagaki T., et al. Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metab. 2008, 8:77-83.
16. Owen B.M., et al. FGF21 contributes to neuroendocrine control of female reproduction. Nat. Med. 2013, 19:1153-1156.
17. Bookout A.L., et al. FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nat. Med. 2013, 19:1147-1152.
18. Liang Q., et al. FGF21 maintains glucose homeostasis by mediating the cross talk between liver and brain during prolonged fasting. Diabetes 2014, Published online July 14, 2014. http://dx.doi.org/10.2337/db14-0541.
19. Laeger T., et al. FGF21 is an endocrine signal of protein restriction. J. Clin. Invest. 2014, 124:3913-3922.
20. De Sousa-Coelho A.L., et al. FGF21 mediates the lipid metabolism response to amino acid starvation. J. Lipid Res. 2013, 54:1786-1797.
21. De Sousa-Coelho A.L., et al. Activating transcription factor 4-dependent induction of FGF21 during amino acid deprivation. Biochem. J. 2012, 443:165-171.
22. Badman M.K., et al. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 2009, 150:4931-4940.
23. Christodoulides C., et al. Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man. J. Clin. Endocrinol. Metab. 2009, 94:3594-3601.
24. Dushay J., et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010, 139:456-463.
25. Galman C., et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab. 2008, 8:169-174.
26. Mraz M., et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin. Endocrinol. (Oxf.) 2009, 71:369-375.
27. Zhang X., et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008, 57:1246-1253.
28. Fisher F.M., et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 2010, 59:2781-2789.
29. Muise E.S., et al. Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor gamma and altered metabolic states. Mol. Pharmacol. 2008, 74:403-412.
30. Dutchak P.A., et al. Fibroblast growth factor-21 regulates PPARgamma activity and the antidiabetic actions of thiazolidinediones. Cell 2012, 148:556-567.
31. Chartoumpekis D.V., et al. Brown adipose tissue responds to cold and adrenergic stimulation by induction of FGF21. Mol. Med. 2011, 17:736-740.
32. Hondares E., et al. Thermogenic activation induces FGF21 expression and release in brown adipose tissue. J. Biol. Chem. 2011, 286:12983-12990.
33. Fisher F.M., et al. FGF21 regulates PGC-1alpha and browning of white adipose tissues in adaptive thermogenesis. Genes Dev. 2012, 26:271-281.
34. Tyynismaa H., et al. Mitochondrial myopathy induces a starvation-like response. Hum. Mol. Genet. 2010, 19:3948-3958.
35. Kim K.H., et al. Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine. Nat. Med. 2013, 19:83-92.
36. Omar B.A., et al. Fibroblast growth factor 21 (FGF21) and glucagon-like peptide 1 contribute to diabetes resistance in glucagon receptor-deficient mice. Diabetes 2014, 63:101-110.
37. Johnson C.L., et al. Fibroblast growth factor 21 reduces the severity of cerulein-induced pancreatitis in mice. Gastroenterology 2009, 137:1795-1804.
38. Wente W., et al. Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 2006, 55:2470-2478.
39. Kharitonenkov A., et al. FGF-21 as a novel metabolic regulator. J. Clin. Invest. 2005, 115:1627-1635.
40. Xu J., et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009, 58:250-259.
41. Fu L., et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004, 145:2594-2603.
42. Tomlinson E., et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002, 143:1741-1747.
43. Kharitonenkov A., et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007, 148:774-781.
44. Veniant M.M., et al. Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys. Endocrinology 2012, 153:4192-4203.
45. Gaich G., et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 2013, 18:333-340.
46. Zhang Y., et al. The starvation hormone, fibroblast growth factor-21, extends lifespan in mice. Elife 2012, 1:e00065.
47. Wei W., et al. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of PPAR-gamma. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:3143-3148.
48. Kuro-o M. Klotho and betaKlotho. Adv. Exp. Med. Biol. 2012, 728:25-40.
49. Ding X., et al. betaKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab. 2012, 16:387-393.
50. Ito S., et al. Impaired negative feedback suppression of bile acid synthesis in mice lacking betaKlotho. J. Clin. Invest. 2005, 115:2202-2208.
51. Adams A.C., et al. FGF21 requires betaklotho to act in vivo. PLoS ONE 2012, 7:e49977.
52. Adams A.C., et al. The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue. Mol. Metab. 2012, 2:31-37.
53. Foltz I.N., et al. Treating diabetes and obesity with an FGF21-mimetic antibody activating the betaKlotho/FGFR1c receptor complex. Sci. Transl. Med. 2012, 4:162ra153.
54. Wu A.L., et al. Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Sci. Transl. Med. 2011, 3:113ra126.
55. Holt J.A., et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 2003, 17:1581-1591.
56. Potthoff M.J., et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1alpha pathway. Cell Metab. 2011, 13:729-738.
57. Shin D.J., Osborne T.F. FGF15/FGFR4 integrates growth factor signaling with hepatic bile acid metabolism and insulin action. J. Biol. Chem. 2009, 284:11110-11120.
58. Song K.H., et al. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology 2009, 49:297-305.
59. Bhatnagar S., et al. Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis. J. Biol. Chem. 2009, 284:10023-10033.
60. Nicholes K., et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am. J. Pathol. 2002, 160:2295-2307.
61. Wu X., et al. FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. J. Biol. Chem. 2010, 285:5165-5170.
62. French D.M., et al. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS ONE 2012, 7:e36713.
63. Kurosu H., et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol. Chem. 2007, 282:26687-26695.
64. Owen B.M., et al. FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell Metab. 2014, 20:670-677.
65. Fisher F.M., et al. Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo. Endocrinology 2011, 152:2996-3004.
66. Holland W.L., et al. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab. 2013, 17:790-797.
67. Lin Z., et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab. 2013, 17:779-789.
68. Hondares E., et al. Hepatic FGF21 expression is induced at birth via PPARalpha in response to milk intake and contributes to thermogenic activation of neonatal brown fat. Cell Metab. 2010, 11:206-212.
69. Veniant M.M., et al. FGF21 promotes metabolic homeostasis via white adipose and leptin in mice. PLoS ONE 2012, 7:e40164.
70. Martens K., et al. Ectopic recombination in the central and peripheral nervous system by aP2/FABP4-Cre mice: implications for metabolism research. FEBS Lett. 2010, 584:1054-1058.
71. Gimeno L., et al. Study of Fgf15 gene expression in developing mouse brain. Gene Expr. Patterns 2003, 3:473-481.
72. Nishimura T., et al. Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain. Biochim. Biophys. Acta 1999, 1444:148-151.
73. Hsuchou H., et al. The fasting polypeptide FGF21 can enter brain from blood. Peptides 2007, 28:2382-2386.
74. Tan B.K., et al. Fibroblast growth factor 21 (FGF21) in human cerebrospinal fluid: relationship with plasma FGF21 and body adiposity. Diabetes 2011, 60:2758-2762.
75. Yang C., et al. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. PLoS ONE 2012, 7:e33870.
76. Sarruf D.A., et al. Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes 2010, 59:1817-1824.
77. Morton G.J., et al. FGF19 action in the brain induces insulin-independent glucose lowering. J. Clin. Invest. 2013, 123:4799-4808.
78. Ryan K.K., et al. Fibroblast growth factor-19 action in the brain reduces food intake and body weight and improves glucose tolerance in male rats. Endocrinology 2013, 154:9-15.
79. Hsuchou H., et al. Fibroblast growth factor 19 entry into brain. Fluids Barriers CNS 2013, 10:32.
80. Arase K., et al. Effects of corticotropin-releasing factor on food intake and brown adipose tissue thermogenesis in rats. Am. J. Physiol. 1988, 255:E255-E259.
81. Kalantaridou S.N., et al. Stress and the female reproductive system. J. Reprod. Immunol. 2004, 62:61-68.
82. Rivier C., Vale W. Corticotropin-releasing factor (CRF) acts centrally to inhibit growth hormone secretion in the rat. Endocrinology 1984, 114:2409-2411.
83. Kalsbeek A., et al. Vasopressin and the output of the hypothalamic biological clock. J. Neuroendocrinol. 2010, 22:362-372.
84. Cannon B., Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol. Rev. 2004, 84:277-359.
85. Nedergaard J., et al. Three years with adult human brown adipose tissue. Ann. N. Y. Acad. Sci. 2010, 1212:E20-E36.
86. Sun H.D., et al. Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys. Am. J. Physiol. Endocrinol. Metab. 2007, 292:E964-E976.
87. Kir S., et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 2011, 331:1621-1624.
88. Wu A.L., et al. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. PLoS ONE 2011, 6:e17868.
89. Wu X., et al. Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19). Proc. Natl. Acad. Sci. U.S.A. 2010, 107:14158-14163.
90. Zhou M., et al. Separating tumorigenicity from bile acid regulatory activity for endocrine hormone FGF19. Cancer Res. 2014, 74:3306-3316.
91. Badman M.K., et al. A very low carbohydrate ketogenic diet improves glucose tolerance in ob/ob mice independent of weight loss. Am. J. Physiol. Endocrinol. Metab. 2009, 297:E1197-E1204.
92. Tyynismaa H., et al. Liver fat but not other adiposity measures influence circulating FGF21 levels in healthy young adult twins. J. Clin. Endocrinol. Metab. 2011, 96:E351-E355.
93. Berglund E.D., et al. Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology 2009, 150:4084-4093.